Hydroxamic acids as matrix metalloproteinase inhibitors.

Area of Science:

• Biochemistry
• Pharmacology
• Medicinal Chemistry

Background:

• Matrix metalloproteinases (MMPs) are crucial for tissue remodeling and extracellular matrix degradation.
• MMPs are implicated in various pathologies, making them significant pharmaceutical targets.
• Over 25 years of research have yielded synthetic matrix metalloproteinase inhibitors (MMPIs).

Purpose of the Study:

• To review hydroxamic acid-based MMPIs.
• To discuss their mechanism of interaction, SAR, QSAR, and clinical development.
• To highlight advancements in selective MMP inhibition.

Main Methods:

• Review of existing literature on MMPIs.
• Analysis of structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR).
• Discussion of traditional, mechanism-based, and structure-based design approaches.

Main Results:

• While many MMPIs yielded disappointing clinical trial results, one (Periostat) is FDA-approved for periodontal disease.
• Selective inhibitors targeting specific MMPs are in various stages of clinical trials for arthritis and cancer.
• Hydroxamic acid-based MMPIs demonstrate high-affinity binding due to their Zn(II)-binding moiety.

Conclusions:

• Hydroxamic acid-based MMPIs represent a promising class of therapeutic agents.
• Continued research combining different design strategies may lead to more effective and selective MMPIs.
• Further development is crucial for treating MMP-associated diseases like arthritis and cancer.